Erratum: The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: A naturalistic study (Therapeutic Drug Monitoring (2013) 35 (84-91) DOI: 10.1097/FTD.0b013e31827a1aad);The relation between dosage, serum concentrations, and clinical outcome in children and adolescents treated with sertraline: A naturalistic study

Therapeutic Drug Monitoring

Volumn 35, Issue 1, 2013, Pages 84-91

  Taurines, Regina ^a   Burger, Rainer ^a   Wewetzer, Christoph ^b   Pfuhlmann, Bruno ^a   Mehler Wex, Claudia ^c   Gerlach, Manfred ^a   Egberts, Karin ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b UNIVERSITY HOSPITAL OF COLOGNE   (Germany)

^c UNIVERSITY OF ULM   (Germany)

Author keywords

child and adolescent psychiatry; sertraline; serum concentrations; side effects; therapeutic drug monitoring

Indexed keywords

SERTRALINE;

ACCOMMODATION DISORDER; ADOLESCENT; ADULT; AGE; AGITATION; ARTICLE; BODY WEIGHT; CARDIOVASCULAR DISEASE; CENTRAL NERVOUS SYSTEM DISEASE; CHILD; CLINICAL GLOBAL IMPRESSION SCALE; CORRELATION ANALYSIS; DEPRESSION; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG ERUPTION; DRUG MONITORING; EXTRAPYRAMIDAL SYMPTOM; FEMALE; GASTROINTESTINAL SYMPTOM; GENDER; HUMAN; MAJOR CLINICAL STUDY; MALE; MENTAL STRESS; POLYDIPSIA; PRIORITY JOURNAL; RATING SCALE; SCHOOL CHILD; SEDATION; SIDE EFFECT; SMOKING HABIT; STEADY STATE; UDVALG FOR KLINISKE UNDERSOGELSER SIDE EFFECT RATING SCALE; UNSPECIFIED SIDE EFFECT; UROGENITAL TRACT DISEASE;

EID: 84872858804     PISSN: 01634356     EISSN: 15363694     Source Type: Journal    
DOI: 10.1097/FTD.0000000000000527     Document Type: Erratum

References (32)

1. Cook EH, Wagner KD, March JS, et al. Long-term sertraline treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2001;40:1175-1181.
2. Pediatric OCD Treatment Study (POTS) Team. Cognitive-behavior therapy, sertraline, and their combination for children and adolescents with obsessive-compulsive disorder: the Pediatric OCD Treatment Study (POTS) randomized controlled trial. JAMA. 2004;292:1969-1976.
3. Asbahr FR, Castillo AR, Ito LM, et al. Group cognitive-behavioral therapy versus sertraline for the treatment of children and adolescents with obsessive-compulsive disorder. J Am Acad Child Adolesc Psychiatry. 2005;44:1128-1136.
4. Alderman J, Wolkow R, Fogel IM. Drug concentration monitoring with tolerability and efficacy assessments during open-label, long-term sertraline treatment of children and adolescents. J Child Adolesc Psychopharmacol. 16:117-129.
5. Ambrosini PJ, Wagner KD, Biederman J, et al. Multicenter open-label sertraline study in adolescent outpatients with major depression. J Am Acad Child Adolesc Psychiatry. 1999;38:566-572.
6. Melvin GA, Tonge BJ, King NJ, et al. A comparison of cognitive-behavioral therapy, sertraline, and their combination for adolescent depression. J Am Acad Child Adolesc Psychiatry. 2006;45:1151-1161.
7. Rynn MA, Siqueland L, Rickels K. Placebo-controlled trial of sertraline in the treatment of children with generalized anxiety disorder. Am J Psychiatry. 2001;158:2008-2014.
8. Wagner KD, Ambrosini P, Rynn M, et al. Efficacy of sertraline in the treatment of children and adolescents with major depressive disorder: two randomized controlled trials. JAMA. 2003;290:1033-1041.
9. Tsapakis EM, Soldani F, Tondo L, et al. Efficacy of antidepressants in juvenile depression: meta-analysis. Br J Psychiatry. 2008;193:10-17.
10. Walkup JT, Albano AM, Piacentini J, et al. Cognitive behavioral therapy, sertraline, or a combination in childhood anxiety. N Engl J Med. 2008; 359:2753-2766.
11. Thomé-Souza MS, Kuczynski E, Valente KD. Sertraline and fluoxetine: safe treatments for children and adolescents with epilepsy and depression. Epilepsy Behav. 2007;10:417-425.
12. Carlson JS, Kratochwill TR, Johnston HF. Sertraline treatment of 5 children diagnosed with selective mutism: a single-case research trial. J Child Adolesc Psychopharmacol. 1999;9:293-306.
13. Steingard RJ, Zimnitzky B, DeMaso DR, et al. Sertraline treatment of transition-associated anxiety and agitation in children with autistic disorder. J Child Adolesc Psychopharmacol. 1997;7:9-15.
14. McDougle CJ, Brodkin ES, Naylor ST, et al. Sertraline in adults with pervasive developmental disorders: a prospective open-label investigation. J Clin Psychopharmacol. 1998;18:62-66.
15. Chermá MD, Ahlner J, Bengtsson F, et al. Antidepressant drugs in children and adolescents: analytical and demographic data in a naturalistic, clinical study. J Clin Psychopharmacol. 2011;31:98-102.
16. Hiemke C, Baumann P, Bergemann N, et al. AGNP consensus guidelines for therapeutic drug monitoring in psychiatry: Update 2011. Pharmacopsychiatry. 2011;44:195-235.
17. Lundmark J, Reis M, Bengtsson F. Therapeutic drug monitoring of sertraline: Variability factors as displayed in a clinical setting. Ther Drug Monit. 2000;22:446-454.
18. Ronfeld RA, Tremaine LM, Wilner KD. Pharmacokinetics of sertraline and its N-demethyl metabolite in elderly and young male and female volunteers.Clin Pharmacokinet. 1997;32(suppl 1):22-30.
19. Safer DJ, Zito JM. Treatment-emergent adverse events from selective serotonin reuptake inhibitors by age group: children versus adolescents. J Child Adolesc Psychopharmacol. 2006;16:159-169.
20. Gerlach M, Hünnerkopf R, Rothenhöfer S, et al. Therapeutic drug monitoring of quetiapine in adolescents with psychotic disorders. Pharmacopsychiatry. 2007;40:72-76.
21. Mehler-Wex C, Kölch M, Kirchheiner J, et al. Drug monitoring in child and adolescent psychiatry for improved efficacy and safety of psychopharmacotherapy. Child Adolesc Psychiatry Ment Health. 2009;3:14.
22. Egberts KM, Mehler-Wex C, Gerlach M. Therapeutic drug monitoring in child and adolescent psychiatry. Pharmacopsychiatry. 2011;44: 249-253.
23. Klampfl K, Taurines R, Preuss A, et al. Serum concentrations, therapeutic response and side effects in children and adolescents with impulsiveaggressive symptoms during risperidone therapy. Pharmacopsychiatry. 2010;43:58-65.
24. Baumann P, Hiemke C, Ulrich S, et al. The AGNP-TDM expert group consensus guidelines: Therapeutic drug monitoring in psychiatry. Pharmacopsychiatry. 2004;37:243-265.
25. Guy W. Ecdeu Assessment Manual. Rockville, MD: National Institute of Mental Health; 1976.
26. Lingjaerde O, Ahlfors UG, Bech P, et al. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand Suppl. 1987;334: 1-100.
27. Reis M, Aamo T, Spigset O, et al. Serum concentrations of antidepressant drugs in a naturalistic setting: compilation based on a large therapeutic drug monitoring database. Ther Drug Monit. 2009;31:42-56.
28. Kanamori M, Takahashi H, Echizen H. Developmental changes in the liver weight- and body weight-normalized clearance of theophylline, phenytoin and cyclosporine in children. Int J Clin Pharmacol Ther. 2002;40:485-492.
29. Balant-Gorgia AE, Balant LP. Milestones in clinical pharmacology. Therapeutic drug monitoring of antidepressants. Clin Ther 1992;14: 612-614; discussion 611.
30. Hiemke C, Härtter S. Pharmacokinetics of selective serotonin reuptake inhibitors. Pharmacol Ther. 2000;85:11-28.
31. Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C] DASB positron emission tomography study. Am J Psychiatry. 2004;161: 826-835.
32. Gerlach M, Rothenhöfer S, Mehler-Wex C, et al. Therapeutisches Drug-Monitoring in der Kinder- und Jugendpsychiatrie-Grundlagen und praktische Empfehlungen. Z Kinder Jugendpsychiatr Psychother. 2006;34:5-13.